James Ahern of Laidlaw
James Ahern is an investment banker, venture capitalist based in New York City.
James serves as managing partner of leading healthcare-focused investment bank Laidlaw & Company UK Ltd., and is the founder of venture capital subsidiary company, Laidlaw Venture Partners.
Opinions
- 19 Jul 2022
A Pandemic Legacy: Saving Lives
The devastating impact of the COVID-19 pandemic is continuing to be felt, both in terms of human cost and the destruction it has wrought on the economies of the world. However, there looks to be a silver lining to the COVID cloud in the shape of medical research.
- August 23, 2022
Open source resources are paving the way for discovery and innovation across countless disciplines. Scholars, scientists and software developers alike are realizing the benefits that this type of collaboration can have for their respective industries and the world as a whole, as they work toward making open source a standard practice. Numerous verticals have demonstrated how open source software allows developers to balance customization. The seamless integration creates better products and more satisfactory user experiences, yet the healthcare industry has proven to be more apprehensive. In order for healthtech companies to get the maximum benefits of the open source community, they’ll need to address these three concerns.
- April 29, 2022
Networking can get a bad rap, with the word bringing back the horror of having to make small talk at awkward events. However, at its core, effective networking is simply a case of identifying and forming mutually beneficial relationships.
Some aspects of networking are specific to investors, whereas others are particularly relevant to entrepreneurs and business founders. However, the two groups share one thing in common: they need each other to thrive. They are (or should be) looking for that new relationship that kick-starts the business or opens the door to a fantastic new investment opportunity.
News
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Poster Presentation at the Military Health System Research Symposium Lucius Partners Logo
- Oct 26, 2022
The MHSRS is the Department of Defense’s largest scientific meeting and is designed to highlight new scientific approaches to address DoD research priorities. Military leaders, academic researchers, and industry present and collaborate on research / health care initiatives falling under numerous topic areas including Military Infectious Diseases.
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study
- Jul 14, 2022
NEW YORK, July 14, 2022 /PRNewswire/ — Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that data from the previously announce Study ‘098 demonstrated clear Proof-of Concept for VTX-067 in the treatment of HPV related cancers. This is a well-validated murine model of HPV related cancers.
Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology
- June 30, 2022
Lucius Partners, LLC has reported that its portfolio company, Voltron Therapeutics, Inc., had announced the initiation of a preclinical study of its novel vaccine candidate VTX-067 in an immune-oncology model. This study, if successful, may support filing of an Investigational New Drug (IND) application with the US Food and Drug Administration.
